Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07013747RecruitingPhase 1/Phase 2
Acne mRNA vaccine for mild acne
This trial tests an mRNA vaccine designed to treat mild facial acne. It aims to see if the vaccine is safe and effective at reducing acne lesions.
Encino, CaliforniaAges 18–45 - NCT07018323RecruitingPhase 2
Study of IMVT-1402 for Graves' disease
This trial tests an investigational drug called IMVT-1402 for people with Graves' disease whose thyroid is still overactive even while taking standard antithyroid medication. The goal is to see if the drug can better control thyroid hormone levels.
Tucson, ArizonaAges 18–75 - NCT06997588RecruitingPhase 2
Testing alpelisib for overgrowth syndrome in children and adults
This trial is testing a drug called alpelisib for people with PROS (a rare condition that causes parts of the body to grow too much). The drug targets a specific gene change (PIK3CA mutation) that is often the cause. If you have this condition and it's causing serious symptoms, this study might help shrink or slow the overgrowth, improving your quality of life.
St Louis, MissouriAges 2–100 - NCT06979336RecruitingPhase 2
New drug for moderate to severe UC
This study tests an experimental drug called RO7837195 for people with moderate to severe ulcerative colitis (UC) who haven't gotten enough help from other treatments. It aims to see if this new drug can reduce inflammation and improve symptoms.
Lancaster, CaliforniaAges 18 years+ - NCT06979453RecruitingPhase 3
A study of deucravacitinib for teens with plaque psoriasis
This trial tests an investigational oral medication called deucravacitinib for teenagers (adolescents) with moderate to severe plaque psoriasis. It aims to see if the drug is safe and works well.
Birmingham, AlabamaAges 12–17 - NCT06945640Enrolling by invitation
Testing a 3D imaging system for robot kidney surgery
This study tests a new 3D imaging system (RUS NE) to help surgeons perform robot-assisted partial nephrectomy more safely and effectively. If you have a small to medium-sized kidney tumor and are already scheduled for this surgery, the researchers want to compare your outcomes to people who had the standard procedure.
SeoulAges 20–80 - NCT06915025RecruitingPhase 3
Study of a new drug for advanced ovarian cancer
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
Orlando, FloridaAges 18 years+ - NCT06913309Recruiting
Home bright light therapy for teen depression
This study tests whether a bright light therapy device you can use at home can help improve depression symptoms in teenagers aged 13-17. It compares the results of using the light with a non-active placebo device.
Beijing, Beijing MunicipalityAges 13–17 - NCT06895499RecruitingPhase 1/Phase 2
Testing a new drug for hidradenitis suppurativa
This trial tests a new medicine called HB0043 for people with moderate to severe hidradenitis suppurativa (a skin condition causing painful lumps). It aims to see if the drug is safe and helps reduce symptoms.
Jinan, ShandongAges 18 years+ - NCT06872125RecruitingPhase 3
Testing zorevunersen for Dravet syndrome
This study tests an experimental drug called zorevunersen for people with Dravet syndrome. It aims to see if the drug can reduce seizures and improve safety.
Phoenix, ArizonaAges 2–17 - NCT06842966RecruitingPhase 2
Testing a new tablet for chronic gallbladder issues
This trial tests an investigational tablet for people with long-term gallbladder inflammation (chronic cholecystitis) or bile duct movement problems (biliary dyskinesia). It aims to see if the tablet reduces stomach pain and other digestive symptoms.
Engel'sAges 18–70 - NCT06842199RecruitingPhase 3
Testing a new pill for moderate to severe plaque psoriasis
This trial tests an experimental drug called ICP-488 for people with moderate to severe plaque psoriasis. It aims to see if the drug can improve symptoms and is safe, and may be an option if you need stronger treatment than creams or light therapy.
Hefei, AnhuiAges 18–75 - NCT06840652Enrolling by invitation
Baclofen for alcohol withdrawal in liver disease
This trial tests if baclofen, a medicine for alcohol dependence, is safe and works for people with chronic liver disease who are actively drinking. It may help you stop drinking alcohol safely.
Sabadell, BarcelonaAges 18–75 - NCT06832410RecruitingPhase 3
Testing VX-880 for type 1 diabetes with a kidney transplant
This trial tests a new treatment called VX-880 for people who have had type 1 diabetes for at least 5 years and have already received a kidney transplant. The goal is to see if VX-880 can improve blood sugar control while you continue your current transplant medications.
Philadelphia, PennsylvaniaAges 18–65 - NCT06808984RecruitingPhase 2
Testing a new drug for agitation in Alzheimer's disease
This trial tests an investigational drug called BMS-986368 to see if it can safely reduce agitation in people with Alzheimer's disease. You may be able to join if you have Alzheimer's with confirmed biomarkers and experience agitation that has been going on for at least 4 weeks.
Homewood, AlabamaAges 55–90 - NCT06809179RecruitingPhase 2
Nasal spray for social anxiety
This study tests if a new nasal spray called fasedienol helps quickly reduce anxiety in adults with social anxiety disorder. The spray is used as needed in a repeat-dose design, meaning you might use it more than once.
Sherman Oaks, CaliforniaAges 18–65 - NCT06782490RecruitingPhase 2
Testing a new drug for MS muscle stiffness
This study tests an investigational drug (BMS-986368) to see if it helps reduce muscle stiffness and spasms caused by multiple sclerosis. It may be an option if you have had spasticity for at least 6 months and are not currently using other treatments that cannot be paused.
Birmingham, AlabamaAges 18–70 - NCT06727604RecruitingPhase 2
Study of IMVT-1402 for Graves' disease not controlled by medication
This trial tests a new drug called IMVT-1402 for adults with Graves' disease whose thyroid is still overactive despite taking antithyroid medication. The goal is to see if the drug can safely help control thyroid hormone levels.
Phoenix, ArizonaAges 18–75 - NCT06735976Recruiting
Safety and effectiveness of LOBO device for PAVM treatment
This study tests a new device (LOBO™) to block abnormal blood vessels in the lungs called PAVMs. It is for people with HHT or similar conditions, and the device is placed into the vessel to reduce the risk of stroke or bleeding. You may be able to join if you have a suitable PAVM that is large enough and you are not taking blood thinners.
Chapel Hill, North CarolinaAges 14 years+ - NCT06709339RecruitingPhase 4
Study of faricimab for Caucasian patients with polypoidal choroidal vasculopathy
This trial tests a drug called faricimab for a type of wet age-related macular degeneration called polypoidal choroidal vasculopathy (PCV). It aims to see if the drug is safe, works well, and how long the effects last in patients who have not been treated before.
MilanAges 50–90 - NCT06697314Recruiting
Clot removal for acute pulmonary embolism with heart strain
This study tests a new device (AlphaVac) that removes blood clots from the lungs using a thin tube inserted through a vein. It may be an option for people with acute pulmonary embolism who have signs of heart strain or low blood pressure.
PoznanAges 18 years+ - NCT06700096RecruitingPhase 3
Testing a new drug for adults with severe hemophilia B
This trial tests a single dose of ANB-002, an experimental therapy for hemophilia B. It aims to see if the drug is safe and effective for people with severe hemophilia B who have been treated with factor IX before and do not have inhibitors.
ChelyabinskAges 18 years+ - NCT06699849RecruitingPhase 2
CSL889 for sickle cell pain crisis
This trial tests a new medicine, CSL889, for people with sickle cell disease who are currently having a pain crisis (vaso-occlusive crisis). The goal is to see if it safely helps reduce the pain and speed recovery.
Oakland, CaliforniaAges 12 years+ - NCT06671548RecruitingPhase 3
Study of relugolix for heavy periods from uterine fibroids
This trial tests if relugolix can reduce heavy menstrual bleeding caused by uterine fibroids. It may be an option for women who want to avoid surgery.
BeijingAges 18 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.